Instructions for Etoricoxib Teva
Release form
tab, film coating, 30 mg: 7, 28, 56 or 98 pcs
tab, film coating, 60 mg: 2, 7, 14, 28, 56 or 98 pcs
tab, film coating, 90 mg: 2, 7, 14, 28, 56 or 98 pcs
Description:
The tablets are covered with a blue film shell, round, double-convex, with an engraving of "30" on one side, the other side is smooth.
1 tab.
Etoricoxib 30 mg
Auxiliary substances: calcium hydrophosphate anhydrous - 38.2 mg, cellulose microcrystalline PH101 - 10.9 mg, cellulose microcrystalline PH 102 - 10.9 mg, A-type Crospovidone - 6 mg, C25 - 3 mg, magnesium stearate - 1 mg.
Film sheath composition: Aquapolish P blue 064.2 MS; (hypromellose- 1.5 mg; hydroxypropyl cellulose (hyprolose) - 0.15 mg; talc - 0.45 mg; triglycerides, medium-chain - 0.15 mg; titanium dioxide (E171) - 0.6 mg; cellulose microcrystalline- 0.1185 mg; indigocarmine-based aluminium varnish (E132) - 0.03 mg; Iron Oxide Red Dye (E172)- 0.0015 mg)
7 pcs. - foil blisters (1) - cardboard packs.
14 pcs. - foil blisters (2) - cardboard packs.
14 pcs. - foil blisters (4) - cardboard packs.
14 pcs. - foil blisters (7) - cardboard packs.
ATC codes
M01AH05 Etoricoxib
Active substance
Etoricoxib
Pharmacotherapy group
NSAIDs
Testimony Etoricoxib:
Symptomatic therapy of osteoarthrosis, rheumatoid arthritis, ankylosing spondylitis; Pain and inflammation symptoms associated with acute podagric arthritis; Short-term treatment of pain associated with dental surgery.
Method of use, course and dosage Etoricoxib:
The preparation is taken orally in a dose of 60-120 mg once/day.
Patients with liver failure (5-9 Child Pugh) are advised not to exceed a daily dose of 60 mg.
Application for kidney disorders
It is contraindicated in severe kidney failure (CC less than 30 ml/min), progressive kidney diseases.
Use in liver disorders
It is contraindicated in severe liver failure (over 9 Child Pugh) or active liver disease. Patients with moderate liver failure (5-9 Child Pugh) are advised not to exceed a daily dose of 60 mg.
Application in elderly patients
It is used with caution in elderly people.
Use in children
It is contraindicated in children and adolescents under 16 years of age.
Nosology (ICD codes)
M05
Seropositive rheumatoid arthritis
M10
Podagra
M15
Polyarthrosis
M19.9
Arthrosis unspecified
M25.5
Joint pain
M45
Ankylosing spondylitis
M47
Spondylosis
R52.0
Acute pain
Pharmacological effect Etoricoxib:
NAPS. The selective COX-2 inhibitor inhibits prostaglandin formation in therapeutic concentrations and has anti-inflammatory, analgesic and antipyretic effects.
Selective suppression of COX-2 is accompanied by a reduction in the expression of clinical symptoms associated with the inflammatory process, with no effect on platelet function and the mucosa of the gastrointestinal tract.
